UCNot yet recruiting

A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UC

Observational · No treatment assigned · 1 site · Tang-Du Hospital

Official record & contacts on ClinicalTrials.gov ↗

In plain English

What this trial is testing

Condition(s) listed: Ulcerative Colitis (UC). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.

Who can join

Ages 18 and older
Any sex

Some of the main requirements, copied from the record:

Age ≥ 18 years at baseline, of any sex.
Have a documented diagnosis of active ulcerative colitis (UC) and be judged by the treating physician as likely to benefit from etrasimod therapy. Active UC is defined as an endoscopic subscore ≥ 2, OR a stool frequency subscore (SFS) ≥ 1,…
Have been receiving etrasimod for no more than 6 months at the time of enrollment.

Plus 1 more requirement(s). There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.

What's involved

About 500 participants are expected to take part.
Start date: 2026-07-15 (planned).
Main results expected around 2027-06-30 (estimate from the record).
1 study site listed in China.

Main thing being measured

Baseline Demographic and Clinical Characteristics of Chinese Adults with Active UC Receiving Etrasimod (Enrollment (baseline))

In the researchers’ words

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes symptoms such as bloody diarrhea, abdominal pain, and frequent bowel movements. It can significantly affect patients' quality of life.

This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.

Questions to ask your doctor and the trial team

Am I likely to qualify, given my health history?
What would I have to do, and how often would I need to visit?
Could I get a placebo? What happens to my current treatment?
What are the possible risks and benefits?
Are travel or other costs covered?
What happens after the trial ends?

Official details

Status	Not yet recruiting
Phase	Observational
Study type	Observational
Conditions	Ulcerative Colitis (UC)
Lead sponsor	Tang-Du Hospital
Collaborators	Shanghai Yicai Feiyang Public Welfare Foundation
Enrollment	500 (estimated)
Start date	2026-07-15
Primary completion (est.)	2027-06-30
First posted	2026-07-15
Last updated	2026-07-15
Official title	Etrasimod for the Treatment of Active UC in Chinese Adults: A National Multicenter Prospective Registry Study (E-HEAL CHINA)
ClinicalTrials.gov ID	NCT07705126

Interventions

Etrasimod (Drug)
Intervention Type: Drug Intervention Name: Etrasimod Description: Etrasimod 2 mg tablet, taken orally once daily (swallowed whole, not crushed or chewed). Participants receive etrasimod as part of routine clinical care. The recommended treatment duration in this registry is at least 52 weeks, but dosing adjustments and discontinuation are at the discretion of the treating physician. Etrasimod is…

Full eligibility criteria (from the record)

Inclusion Criteria:

1. Age ≥ 18 years at baseline, of any sex.
2. Have a documented diagnosis of active ulcerative colitis (UC) and be judged by the treating physician as likely to benefit from etrasimod therapy. Active UC is defined as an endoscopic subscore ≥ 2, OR a stool frequency subscore (SFS) ≥ 1, OR a rectal bleeding subscore (RBS) ≥ 1. Any disease extent (Montreal classification E1, E2, or E3) is eligible. Participants must provide an endoscopy (including sigmoidoscopy) report obtained within 12 months prior to enrollment.
3. Have been receiving etrasimod for no more than 6 months at the time of enrollment.
4. Voluntarily sign a written informed consent form and have the ability to understand and complete study-related questionnaires and visit procedures.

Exclusion Criteria:

1. Have any contraindication to etrasimod use as per the approved prescribing information.
2. Have received prior treatment with ≥ 3 biologic therapies (including infliximab, adalimumab, vedolizumab, guselkumab, risankizumab, and mirikizumab), OR ≥ 2 biologic therapies plus 1 JAK inhibitor (including upadacitinib and tofacitinib).
3. Have any condition that, in the investigator's judgment, may compromise data quality or threaten participant safety. The reason for exclusion must be documented.

Locations (1)

Site	City	Country	Site status
Tangdu Hospital	Xi’an, Shanxi	China

For contacts at each site, use the official record.

Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.